Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chemical Inhibition of Ezh2 Alters Ex Vivo B cell Differentiation and Gene Expression Dynamics

ABSTRACT: To understand the role of Ezh2 in B cell differentiation B cells were stimulated ex vivo with LPS, Il2, and Il5 in the presence of DMSO or the selective Ezh2 inhibitor GSK343. Following 3 days culture, activated B cells and Plasmablasts were FACS isolated and RNA-seq was performed to identify the molecular effects of Ezh2 inhibition on B cell subsets during differentiation.

ORGANISM(S): Mus musculus

PROVIDER: GSE97696 | GEO | 2018/03/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene regulation by EZH2 inhibitors

Project description:Our previous study has found that UNC1999 and GSK343 are potent autophagy inducers. To further investigate the underlying mechanisms, microarray analysis was performed. EZH2 inhibitor-induced gene expression in HCT116 was measured at 4 hours after exposure to 5 uM UNC1999 or 10 uM GSK343.

2016-06-23 | E-GEOD-83633 | biostudies-arrayexpress

ZBTB32 Is an Early Repressor of the CIITA MHC Class II Gene Expression during B Cell Differentiation to Plasma Cells

Project description:Primary murine B cells were stimulated with IL2, IL5, LPS to induce B cell differentiation for 24 hours. RNA was extracted from control and differentiated B cell to compare gene expression. Murine B cells (CD43-) were purfied from 5 weeks old mice splenocytes. And purified B cells were stimulated with IL2, IL5, LPS for 24 hours.

2012-07-30 | E-GEOD-17999 | biostudies-arrayexpress

Treatment of CML CD34+ cells with EZH2 inhibitor GSK343

Project description:Transcriptional profiling by array of CML CD34+ cells to understand the response of chronic myeloid leukaemia stem cells to an EZH2 inhibitor, GSK343.

2016-11-01 | E-MTAB-2893 | biostudies-arrayexpress

Treatment of non-CML CD34+ cells with EZH2 inhibitor GSK343

Project description:Transcriptional profiling of non-CML CD34+ cells to understand the response of non-CML stem cells to an EZH2 inhibitor, GSK343.

2016-11-01 | E-MTAB-3552 | biostudies-arrayexpress

EZH2-dependent chromatin accessibility changes during B cell differentiation

Project description:To understand the role of EZH2 in B cell differentiation, EZH2 was inducibly deleted using tamoxifen and B cells stimulated to differentiate with LPS in vivo. After 3 days, EZH2-sufficient and EZH2-deficient naive B cells and plasmablasts were FACS isolated from the spleens and ATAC-seq was performed to identify the chromatin accessibility changes that are programmed by EZH2.

2017-12-16 | GSE103142 | GEO

Ezh2 loss is associated with functional defects and ectopic gene expression in mature neutrophils

Project description:Gene expression profiling of progenitor and neutrophil-derived HoxB8-ER cells (WT and Ezh2-/-) and neutrophil-derived HOXB8-ER treated with GSK343 and vehicle for 9 days. Ezh2 loss might lead to effective cytopenias caused by dysfunctional mature cells. To test this hypothesis, we examined Ezh2-null murine myeloid cell lines capable of neutrophilic differentiation. Bone marrow cells from Ezh2-/- and controls were immortalized with a HoxB8-estrogen receptor fusion and could be differentiated into mature neutrophils by removing estrogen from the culture medium.Gene expression profiling showed upregulation of oxidative phosphorylation pathway genes and ectopic expression of Gata1 and its associated erythroid gene targets. Functional and gene expression differences observed in Ezh2-/- derived neutrophils could be replicated in controls by treatment with the Ezh2-specific inhibitor GSK343. In conclusion, we demonstrate that Ezh2 loss allows for differentiation of normal appearing, but dysfunctional mature neutrophils characterized by ectopic gene expression and elevated levels of reactive oxygen species. These defects could contribute to the inflammatory bone marrow microenvironment and clinical phenotypes observed in patients with MDS.

2017-11-18 | GSE107061 | GEO

Transcriptional profiling of IRF8 KO B cell differentiation

Project description:To understand the gene expression programs regulated by IRF8 in B cells responding to LPS stimulation we generated IRF8 deficient B cells by CRISPR/Cas9. IRF8 knockout and wild-type CD43- splenic B cells were isolated and directly used for RNA-seq (naive B cells) or simulated to differentiate with LPS, IL2, and IL5 for 3 days. At this time activated Bcells and plasmablasts were sorted for RNA-seq.

2023-06-20 | GSE208254 | GEO

Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni by GSK343 decreases the expression of genes implicated in DNA replication and ncRNA metabolism

Project description:Schistosomiasis is a chronic and debilitating disease caused by a trematode of the genus Schistosoma. The current strategy for the control of the disease involves treatment with Praziquantel, the only available drug. The development of new drugs is therefore a top priority. Drugs that inhibit histone modifying enzymes have been used in cancer, altering gene expression, replication, repair and DNA recombination. Schistosoma parasites have some characteristics similar to malignant tumors, such as intense cell division and high levels of metabolic activity. Here we evaluate in Schistosoma mansoni the effect of GSK343, an inhibitor of the histone methyltransferase EZH2 that had been shown to arrest or reduce the growth of human cancer cells. We show that GSK343 causes damage to the parasite tegument and reduces egg laying in vitro, concomitant with a decrease in levels of H3K27me3, the histone mark put in place by EZH2. RNA-seq and proteomic analyses of treated parasites showed changes in the expression of hundreds of genes involved in important metabolic processes. In females, a marked decrease was observed in the expression of genes related to processes such as DNA replication and noncoding RNA metabolism. In conclusion, the histone methyltransferase EZH2 seems to be a promising novel drug target against schistosomiasis.

2018-11-23 | PXD010342 | Pride

Characterizing transcriptional consequences of EZH2 inhibitor withdrawal for Karpas-422 CXCdel cells

Project description:We characterized the effects that the the withdrawal of the EZH2 inhibitor, GSK343, has on Karpas-422 CXCdel cells

2023-02-08 | GSE199811 | GEO

ZBTB32 Is an Early Repressor of the CIITA MHC Class II Gene Expression during B Cell Differentiation to Plasma Cells

2012-07-31 | GSE17999 | GEO